Progress in research: Daratumumab improves treatment outcomes of patients with AL amyloidosis

Hamza Hassan, Faiz Anwer, Anum Javaid, Hamza Hashmi

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Outcomes for patients with systemic light-chain (AL) amyloidosis have improved over the last two decades with timely diagnosis, use of novel chemotherapeutic agents, risk stratification and better patient selection criteria before hematopoietic autologous stem cell transplant (ASCT). However, majority of patients have advanced stage disease at initial presentation and at relapse rendering them ineligible for intensive cytotoxic chemotherapy or ASCT. Daratumumab (Dara) with or without standard chemotherapy appears to be an excellent treatment option for newly diagnosed and relapsed refractory AL amyloidosis. This is largely due to its tolerable safety and remarkable efficacy as seen in multiple retrospective, small phase II studies as well as a phase III randomized controlled trial. Here we review published clinical trials and retrospective data of Dara in AL amyloidosis that explore its role as a valuable addition to the treatment armamentarium for this challenging disease.

Original languageEnglish (US)
Article number103435
JournalCritical Reviews in Oncology/Hematology
StatePublished - Sep 2021


  • AL amyloidosis
  • Daratumumab
  • Light chain amyloidosis
  • Newly diagnosed
  • Relapsed refractory

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Progress in research: Daratumumab improves treatment outcomes of patients with AL amyloidosis'. Together they form a unique fingerprint.

Cite this